William Mobley,
Distinguished Professor and Chair, Department of Neurosciences,
University of California-San Diego
William C. Mobley is a Distinguished Professor and Chair of the Department of Neurosciences at UCSD. He also serves as Executive Director of UCSD's Down Syndrome Center for Research and Treatment and is the Florence Riford Chair of Alzheimer Disease Research. He came to UCSD in June 2009 from Stanford University in Palo Alto, Calif., where he served as the John E. Cahill Family Professor in the Department of Neurology and Neurological Sciences and was the founding director of the Neuroscience Institute. Dr. Mobley has a distinguished record of academic achievement and is considered one of the most prominent academic neurologists in the US. He has an international reputation for his research on degenerative disease of the central nervous system as well as being a leader in translational medicine, bridging clinical and basic science. Dr. Mobley earned his Ph.D. from Stanford University in Neuro- & Behavioral Science in 1974, and an M.D. from the same institution in 1976. He then completed an internship in pathology in 1977, also at Stanford, and went on to complete a residency and fellowship in neurology and pediatric neurology at The Johns Hopkins University in 1982. While there he was selected to serve as Chief Resident in Pediatric Neurology from 1981 to 1982. In 1983, he became certified by the American Board of Pediatrics and in 1987 was certified by the American Board of Psychiatry and Neurology with Special Competence in Child Neurology.
Novel Biomarker Development in Down's Syndrome and Other CNS Disorders
Friday, 16 January 2015 at 14:30
Add to Calendar ▼2015-01-16 14:30:002015-01-16 15:30:00Europe/LondonNovel Biomarker Development in Down's Syndrome and Other CNS DisordersPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Down syndrome is caused by the presence within the genome of a third copy of chromosome 21. People with Down syndrome have a number of medical issues that must be confronted. During recent decades, the problems faced by children with Down syndrome, especially congenital heart disease, have been much more effectively treated. The result is that average longevity has increased from less than 10 years of age in the early 1900s to more than 60 at this time. With continuing advances in medical care, longevity is likely to increase further. While a boon to the wellbeing of people with Down syndrome and their families, the result is that more are now approaching the age at which age-related changes in brain function are ensuing. Indeed, beyond the problems with cognition experienced by all children with Down syndrome, essentially all of those at age 40 years have the brain pathology characteristic of Alzheimer disease and the majority are demented by age 60. The remarkable fact is that Down syndrome population thus represents by far the largest in which genetic changes are responsible for Alzheimer disease. We are particularly interested in the biology of Down syndrome, especially as it encompasses Alzheimer disease. Indeed, it is a very real possibility that studies of Alzheimer disease in Down syndrome will elucidate the earliest events in Alzheimer disease in the general population and create opportunities for effective new treatments for this disease. To define the biology of Alzheimer disease in Down syndrome we need first to elucidate the natural history of brain again in Down syndrome. We will discuss recent studies in which important new findings regarding natural history have been uncovered. In addition, we will discuss the possible contributions from additional studies and clinical trials in this important population.
Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-01-16 14:30:002015-01-16 15:30:00Europe/LondonNovel Biomarker Development in Down's Syndrome and Other CNS DisordersPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
